RedHill Biopharma starts Phase 2 trial for advanced prostate cancer treatment using opaganib

From Nasdaq: 2025-02-04 17:26:39

RedHill Biopharma has started a Phase 2 trial to evaluate opaganib’s effectiveness in enhancing darolutamide for treating metastatic castrate-resistant prostate cancer. The study, sponsored by Bayer and the Ramsay Hospital Research Foundation, aims to improve 12-month radiographic progression-free survival for 80 patients resistant to standard treatment. Opaganib, a sphingosine kinase-2 inhibitor, may help overcome drug resistance in patients with mCRPC. This research could potentially lead to a breakthrough in managing treatment-resistant prostate cancer, benefiting the 1.5 million people affected annually. RDHL stock closed at $5.82, up 1.22% on the Nasdaq.



Read more at Nasdaq: RedHill Biopharma Launches Phase 2 Trial For Advanced Prostate Cancer Treatment